Primary evaluation and management of statin therapy complications

Dean Seehusen, Chad Alan Asplund, Dawn R. Johnson, Kevin A. Horde

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

HMG-CoA reductase inhibitors (statins) have become one of the most commonly prescribed classes of medications in the United States. While serious adverse events are rare, less serious events are frequently seen. Published guidelines recommend initial screening labs as well as ongoing monitoring of liver enzymes during therapy. Up to 5% of patients will have some muscle complaints while taking statins. Therefore, primary care clinicians will often be faced with real or potential complications of statin therapy. There are well established risk factors for development of these complications. Being aware of a patient's risk and using the lowest effective dose minimizes the occurrence of adverse events. The great majority of these abnormalities either do not require discontinuation of therapy or require only brief interruption of therapy. Judicious and systematic use of laboratory testing will minimize needless evaluation and premature discontinuation of statin therapy.

Original languageEnglish (US)
Pages (from-to)250-256
Number of pages7
JournalSouthern medical journal
Volume99
Issue number3
DOIs
StatePublished - Mar 1 2006

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Therapy
Therapeutics
Primary Health Care
Guidelines
Muscles
Liver

Keywords

  • Adverse effects
  • Cholesterol
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Liver function tests
  • Myopathy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Primary evaluation and management of statin therapy complications. / Seehusen, Dean; Asplund, Chad Alan; Johnson, Dawn R.; Horde, Kevin A.

In: Southern medical journal, Vol. 99, No. 3, 01.03.2006, p. 250-256.

Research output: Contribution to journalReview article

Seehusen, Dean ; Asplund, Chad Alan ; Johnson, Dawn R. ; Horde, Kevin A. / Primary evaluation and management of statin therapy complications. In: Southern medical journal. 2006 ; Vol. 99, No. 3. pp. 250-256.
@article{ed3c01e845124d67b98869b9ec9a8de5,
title = "Primary evaluation and management of statin therapy complications",
abstract = "HMG-CoA reductase inhibitors (statins) have become one of the most commonly prescribed classes of medications in the United States. While serious adverse events are rare, less serious events are frequently seen. Published guidelines recommend initial screening labs as well as ongoing monitoring of liver enzymes during therapy. Up to 5{\%} of patients will have some muscle complaints while taking statins. Therefore, primary care clinicians will often be faced with real or potential complications of statin therapy. There are well established risk factors for development of these complications. Being aware of a patient's risk and using the lowest effective dose minimizes the occurrence of adverse events. The great majority of these abnormalities either do not require discontinuation of therapy or require only brief interruption of therapy. Judicious and systematic use of laboratory testing will minimize needless evaluation and premature discontinuation of statin therapy.",
keywords = "Adverse effects, Cholesterol, Hydroxymethylglutaryl-CoA reductase inhibitors, Liver function tests, Myopathy",
author = "Dean Seehusen and Asplund, {Chad Alan} and Johnson, {Dawn R.} and Horde, {Kevin A.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1097/01.smj.0000202691.52352.55",
language = "English (US)",
volume = "99",
pages = "250--256",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Primary evaluation and management of statin therapy complications

AU - Seehusen, Dean

AU - Asplund, Chad Alan

AU - Johnson, Dawn R.

AU - Horde, Kevin A.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - HMG-CoA reductase inhibitors (statins) have become one of the most commonly prescribed classes of medications in the United States. While serious adverse events are rare, less serious events are frequently seen. Published guidelines recommend initial screening labs as well as ongoing monitoring of liver enzymes during therapy. Up to 5% of patients will have some muscle complaints while taking statins. Therefore, primary care clinicians will often be faced with real or potential complications of statin therapy. There are well established risk factors for development of these complications. Being aware of a patient's risk and using the lowest effective dose minimizes the occurrence of adverse events. The great majority of these abnormalities either do not require discontinuation of therapy or require only brief interruption of therapy. Judicious and systematic use of laboratory testing will minimize needless evaluation and premature discontinuation of statin therapy.

AB - HMG-CoA reductase inhibitors (statins) have become one of the most commonly prescribed classes of medications in the United States. While serious adverse events are rare, less serious events are frequently seen. Published guidelines recommend initial screening labs as well as ongoing monitoring of liver enzymes during therapy. Up to 5% of patients will have some muscle complaints while taking statins. Therefore, primary care clinicians will often be faced with real or potential complications of statin therapy. There are well established risk factors for development of these complications. Being aware of a patient's risk and using the lowest effective dose minimizes the occurrence of adverse events. The great majority of these abnormalities either do not require discontinuation of therapy or require only brief interruption of therapy. Judicious and systematic use of laboratory testing will minimize needless evaluation and premature discontinuation of statin therapy.

KW - Adverse effects

KW - Cholesterol

KW - Hydroxymethylglutaryl-CoA reductase inhibitors

KW - Liver function tests

KW - Myopathy

UR - http://www.scopus.com/inward/record.url?scp=33645107206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645107206&partnerID=8YFLogxK

U2 - 10.1097/01.smj.0000202691.52352.55

DO - 10.1097/01.smj.0000202691.52352.55

M3 - Review article

C2 - 16553099

AN - SCOPUS:33645107206

VL - 99

SP - 250

EP - 256

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 3

ER -